Plasma transforming growth factor-β1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker

Lung Cancer

Volumn 16, Issue 1, 1996, Pages 47-59

  Kong, Feng Ming ^a   Washington, Mary Kay ^a   Jirtle, Randy L ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

lung cancer; radiotherapy; transforming growth factor 1 (TGF 1); tumor marker

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER EPIDEMIOLOGY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031040409     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(96)00611-3     Document Type: Article

References (29)

1. [1] Brattain MG, Howell G, Sun L, Willson JKV. Growth factor balance and tumor progression. Curr Opin Oncol 1994; 6: 77-81.
2. [2] Delvenne CG, Winkler-Gol RA, Piccart MJ et al. Expression of c-erbB2, TGFβ1 and pS2 genes in primary human breast cancers. Eur J Cancer 1992; 28: 700-705.
3. [3] Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor-β requires binding to the cation-independent mannose-6-phosphate/insulin-like growth factor Type II receptor. Proc Natl Acad Sci USA 1991; 88: 580-584.
4. [4] Derynck R, Goeddel DV, Ullrich A et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707-712.
5. [5] De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose-6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 1725-1729.
6. [6] De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2r gene is mutated in human hepatocellular carcinomas with LOH. Nature Genet 1995; 11:447-449.
7. [7] Filmus J, Kerbel RS. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-β during tumor progression. Curr Opin Oncol 1993; 5: 123-129.
8. [8] Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 1993; 4: 493-540.
9. [9] Inoue T, Ishida T, Takenoyama M, Sugio K, Sugimachi K. The relationship between the immunodetection of transforming growth factor-β in lung adenocarcinoma and longer survival rates. Surg Oncol 1995; 4: 51-57.
10. [10] Ito N, Kawata S, Tamura S et al. Elevated levels of transforming growth factor-β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991; 51: 4080-4083.
11. [11] Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGFβ1 in patients with invasive prostate cancer. Nature Med 1995; 1: 282-283.
12. [12] Jakowlew S, Mathias A, Chung P, Moody TW. Expression of transforming growth factor-β ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995; 6: 465-476.
13. [13] Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D. Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 1990; 2: 149-155.
14. [14] Kim S-J, Kehrl JH, Burton J et al. Transactivation of the transforming growth factor β1 (TGFβ1) gene by human T lymphotrophic virus Type 1 tax: a potential mechanism for increased production of TGFβ1 in adult T cell leukemia. J Exp Med 1990; 172: 121.
15. [15] Kimchi A, Wang SF, Weinberg RA, Cheifetz S, Massagué J. Absence of TGFβ receptors and growth inhibitory responses in retinoblastoma cells. Science (Washington DC) 1988; 240: 196-198.
16. [16] Kong F-M, Anscher MS, Abbot BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155-162.
17. [17] Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science (Washington DC) 268: 1336-1338, 1995.
18. [18] Mooradian DL, McCarthy JB, Komanduri KV, Furcht LT. Effects of transforming growth factor-β1 on human pulmonary adenocarcinoma cell adhesion, motility and invasion in vitro. J Natl Cancer Inst 1992; 84: 523-527.
19. [19] Newman MJ. Transforming growth factor-β and the cell surface in tumor progression. Cancer Metastasis Rev 1993; 12: 239-254.
20. [20] Norgaard P, Damstrup L, Rygaard K, Spang-Thomsen M. Growth suppression by transforming growth factor-β1 of human small cell lung cancer cell lines is associated with expression of the Type II receptor. Br J Cancer 1994; 69: 802-808.
21. [21] Perrotti D, Cimino L, Ferrari S, Sacchi A. Differential expression of transforming growth factor-β1 gene in 3LL metastatic variants. Cancer Res 1991; 51: 5491-5494.
22. [22] Schwarz LC, Wright JA, Gingras M-C et al. Aberrant TGF-β production and regulation in metastatic malignancy. Growth Factors 1990; 3: 115-127.
23. [23] Schwartz MK. Cancer markers. In: VT DeVita Jr, S Hellman and SA Rosenberg editors, Cancer Principles and Practice of Oncology. Philadelphia: Lippincott Co., 1993: 531-542.
24. [24] Shirai Y, Kawata S, Tamura S et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer 1994; 73: 2275-2279.
25. [25] Shirai Y, Kawata S, Ito N et al. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992; 83: 676-679.
26. [26] Sue SR, Chari RS, Kong F-M et al. Transforming growth factor-β receptors and mannose-6-phosphate/insulin-like growth factor II receptor expression in human hepatocellular carcinomas. Ann Surg 222: 171-178, 1995.
27. [27] Wakefield LM, Letterio JJ, Chen T et al. Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1: 129-136.
28. [28] Wakefield LM, Smith DM, Masui T, Harris CC, Sporn MB. Distribution and modulation of the cellular receptor for transforming growth factor-β. J Cell Biol 1987; 105: 965-975.
29. [29] Wright JA, Turley EA, Greenberg AH. Transforming Growth factor-β and fibroblast growth factor as promoters of tumor progression to malignancy. Crit Rev Oncol 1993; 4: 473-492.